Clinical Trial of Marijuana for Cancer Pain Annouced
Tetra Bio-Pharma’s PPP001 is the first smokeable cannabis drug product being developed for the treatment of pain in late-stage cancer patients. If approved by the FDA, the company’s PPP001 will be sold as a titanium pipe and blister pack containing drug pellets with a standardized amount of THC and CBD. A single drug pellet is pushed out of the blister pack, inserted into the titanium pipe, and smoked to deliver the active ingredients.Tetra's Management anticipates securing marketing approval in Canada and the United States by early 2019.
The development of PPP001 will confirm the efficacy of smoked cannabis in treating underlying medical conditions and essentially validate the use of medical marijuana.